Purpose: Bevacizumab (B) plus chemotherapy (CT) is a common choice for first-line treatment of metastatic colorectal cancer. Molecular predictors of B efficacy have still not been identified. We analyzed the role of 22 angiogenesis-associated proteins in patient outcome. Patients and methods: Serum samples collected at baseline and at the first clinical evaluation were available for 58 patients enrolled in the randomized multicenter ITACa trial and who received CT+ B. Serum protein levels were determined using multiplex ELISA. Results: Patients with baseline ≥145 pg/mL IL-8 showed shorter median progression-free survival and overall survival (OS) than those with lower levels (6.5 vs 6. 12.6 months; HR 7.39, P<0.0001 and 8.7 vs 28.8 month...
Despite advances in the treatment of colorectal cancer (CRC), it remains the second most common caus...
Colorectal cancer is one of the most common cancers worldwide. The prognosis of patients with metast...
BACKGROUND: No biomarkers exist to predict benefit from antiangiogenic therapy in metastatic colorec...
Purpose: Bevacizumab (B) plus chemotherapy (CT) is a common choice for first-line treatment of metas...
BACKGROUND: In spite of demonstrating prognostic and possibly predictive benefit in retrospective co...
BACKGROUND: The combination of chemotherapy with the vascular endothelial growth factor (VEGF) antib...
Background In spite of demonstrating prognostic and possibly predictive benefit in retrospective coh...
BACKGROUND: Bevacizumab prolongs progression-free survival (PFS) in patients with metastatic colorec...
BACKGROUND: To identify whether circulating levels of angiogenesis-related factors may be predictiv...
PURPOSE: We aimed to investigate the role of apolipoprotein A-I (ApoA-I) as a predictor of prognosis...
OBJECTIVE: The anti-vascular endothelial growth factor (VEGF) antibody bevacizumab has received cons...
The need to identify biomarkers for bevacizumab-based treatment in advanced colorectal cancer is imp...
International audienceBackground: Several studies have reported the impact of single nucleotide poly...
Abstract Background Colorectal cancer is the third most common cancer and the third leading cause of...
PubMedID: 23464465Background: No factor has thus far been identified to predict the efficacy of beva...
Despite advances in the treatment of colorectal cancer (CRC), it remains the second most common caus...
Colorectal cancer is one of the most common cancers worldwide. The prognosis of patients with metast...
BACKGROUND: No biomarkers exist to predict benefit from antiangiogenic therapy in metastatic colorec...
Purpose: Bevacizumab (B) plus chemotherapy (CT) is a common choice for first-line treatment of metas...
BACKGROUND: In spite of demonstrating prognostic and possibly predictive benefit in retrospective co...
BACKGROUND: The combination of chemotherapy with the vascular endothelial growth factor (VEGF) antib...
Background In spite of demonstrating prognostic and possibly predictive benefit in retrospective coh...
BACKGROUND: Bevacizumab prolongs progression-free survival (PFS) in patients with metastatic colorec...
BACKGROUND: To identify whether circulating levels of angiogenesis-related factors may be predictiv...
PURPOSE: We aimed to investigate the role of apolipoprotein A-I (ApoA-I) as a predictor of prognosis...
OBJECTIVE: The anti-vascular endothelial growth factor (VEGF) antibody bevacizumab has received cons...
The need to identify biomarkers for bevacizumab-based treatment in advanced colorectal cancer is imp...
International audienceBackground: Several studies have reported the impact of single nucleotide poly...
Abstract Background Colorectal cancer is the third most common cancer and the third leading cause of...
PubMedID: 23464465Background: No factor has thus far been identified to predict the efficacy of beva...
Despite advances in the treatment of colorectal cancer (CRC), it remains the second most common caus...
Colorectal cancer is one of the most common cancers worldwide. The prognosis of patients with metast...
BACKGROUND: No biomarkers exist to predict benefit from antiangiogenic therapy in metastatic colorec...